| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/01/2007 | US20070026073 Amorphous efavirenz and the production thereof |
| 02/01/2007 | US20070026072 Benzoquinones of enhanced bioavailability |
| 02/01/2007 | US20070026071 Magnesium salt proton pump inhibitor dosage forms |
| 02/01/2007 | US20070026070 Cross-linked polysaccharide composition |
| 02/01/2007 | US20070026067 Liquid formulations for controlled delivery of benzisoxazole derivatives |
| 02/01/2007 | US20070026065 Solid, modified-release pharmaceutical dosage forms which can be administered orally |
| 02/01/2007 | US20070026063 Composition for coating comprising low-substituted cellulose ether and coated preparation having unpleasant taste masked |
| 02/01/2007 | US20070026062 Gemfibrozil, fenofibrate, bezafibrate, clofibrate, ciprofibrate and active metabolites and analogues dissolved in a vehicle, which is hydrophobic, hydrophilic or water-miscible; improved bioavailability of the active ingredient upon oral administration; administered to the patient in fed or fasted state |
| 02/01/2007 | US20070026061 Liposomal formulation and use thereof |
| 02/01/2007 | US20070026060 Method for treating advanced ovarian cancer |
| 02/01/2007 | US20070026059 Ligands for orphan nuclear hormone receptor steroidogenic factor-1 (SF-1) |
| 02/01/2007 | US20070026058 Method and composition for treating rhinitis |
| 02/01/2007 | US20070026057 In vivo targeting of dendritic cells |
| 02/01/2007 | US20070026056 Antiviral patch |
| 02/01/2007 | US20070026054 Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease |
| 02/01/2007 | US20070026052 Hemostatic material |
| 02/01/2007 | US20070026051 Use of tripolidine in providing refreshedness on waking |
| 02/01/2007 | US20070026050 Mortierella schmuckeri microorganisms are cultured in fermentation medium; a polyunsaturated fatty acid for use in e.g. infant formulas |
| 02/01/2007 | US20070026049 Method of increasing lean body mass and reducing body fat mass in infants |
| 02/01/2007 | US20070026042 System for treating aneurysmal disease |
| 02/01/2007 | US20070026041 PEA-TEMPO/PEA-BZ coatings for controlled delivery of drug from implantable medical devices |
| 02/01/2007 | US20070026037 Devices, articles, coatings, and methods for controlled active agent release or hemocompatibility |
| 02/01/2007 | US20070026036 Drug/Drug Delivery Systems for the Prevention and Treatment of Vascular Disease |
| 02/01/2007 | US20070026035 Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices |
| 02/01/2007 | US20070026034 Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices |
| 02/01/2007 | US20070026033 Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices |
| 02/01/2007 | US20070026027 Human chorionic gonadotropin (hCG) formulations for facilitating weight loss and body contouring |
| 02/01/2007 | US20070026026 Oral liquid losartan compositions |
| 02/01/2007 | US20070026015 Method |
| 02/01/2007 | US20070026014 Interferon beta in severe acute respiratory syndrome (sars) |
| 02/01/2007 | US20070025999 Treatment with anti-vegf antibodies |
| 02/01/2007 | US20070025998 Methods for enhancing the efficacy of cancer therapy |
| 02/01/2007 | US20070025996 Oculospanin as a tumor specific antigen and methods and compositions utilizing same |
| 02/01/2007 | US20070025993 Tek antagonists |
| 02/01/2007 | US20070025989 Administration of agents for the treatment of inflammation |
| 02/01/2007 | US20070025987 Method for Treating Vasculitis |
| 02/01/2007 | US20070025986 Modulation of HCN channels by second messengers |
| 02/01/2007 | US20070025968 Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes |
| 02/01/2007 | US20070025964 administering an effective amount of beta -D-D4FC or its ester or salt to the human in combination or alternation with a second drug selected from abacavir, indinavir, nelfinavir, saquinavir, amprenavir, efavirenz, delavirdine, nevirapine for the treatment of an HIV infection in human |
| 02/01/2007 | US20070025960 Bisphosphonates for prophylaxis and therapy against bioterrorism agents |
| 02/01/2007 | US20070025959 Adjuvant combination formulations |
| 02/01/2007 | US20070025956 Polymer-based compositions and conjugates of non-steroidal anti-inflammatory drugs |
| 02/01/2007 | US20070025955 Tissue adhesive sealant |
| 02/01/2007 | US20070025954 Ionene polymers and their use as antimicrobial agents |
| 02/01/2007 | US20070025953 Co-therapy for diabetic conditions |
| 02/01/2007 | US20070025952 Linear cyclodextrin copolymers |
| 02/01/2007 | US20070025951 Skin care compositions containing xanthones |
| 02/01/2007 | US20070025950 Composition and method for treating cellulite |
| 02/01/2007 | US20070025948 Dilution-type sterilizer composition |
| 02/01/2007 | US20070025933 Photoprotector and/or photoimmunoprotector compositions of the skin and their uses |
| 02/01/2007 | US20070025927 Odorless formulation for treating mucosal discontinuities |
| 02/01/2007 | US20070025926 Preventing and reversing the formation of advance glycosylation endproducts |
| 02/01/2007 | US20070025925 Method of attenuating neurogenic swelling or neurogenic inflammation |
| 02/01/2007 | US20070025924 Method of attenuating swelling or inflammation |
| 02/01/2007 | US20070025923 Use of ciclesonide for the treatment of respiratory diseases |
| 02/01/2007 | US20070025922 Method of attenuating neurogenic pain |
| 02/01/2007 | US20070025921 Inhibition of olfactory neurosensory function to treat eating disorders and obesity |
| 02/01/2007 | US20070025920 Stable Pharmaceutical Solution Formulations for Pressurized Metered Dose Inhalers |
| 02/01/2007 | US20070025913 Immunoglobulin which specifically binds endothelial cell-specific polypeptides; for use as evaluative tool in immunodiagnostic and drug efficacy studies |
| 02/01/2007 | DE112005000612T5 Zusammensetzung zur Stabilisierung von Epigallocatechingallat (EGCG) in Wasserphase und Herstellungsverfahren davon Stabilization composition of epigallocatechin gallate (EGCG) in water phase and manufacturing method thereof |
| 02/01/2007 | DE10301917B4 Verwendung von Substanzen der Porphyrinsynthese bei der Phototherapie von Haut- oder Gelenkerkrankungen des Menschen oder von Säugetieren Use of substances of the porphyrin synthesis in the phototherapy of skin or joint disease of humans or mammals |
| 02/01/2007 | DE102005035917A1 Use of isocitrate-/isocitric acid derivatives, in the preparation of medicament to reduce sequences of aging-conditions mutations in cells of an organism |
| 02/01/2007 | DE102005035742A1 New cyclobut-3-ene-1,2-dione derivatives are kinase inhibitors useful for treating e.g. cancer, hypertension, diabetes, glaucoma and bacterial infections |
| 02/01/2007 | DE102005034484A1 Verfahren zur Herstellung von Glimepirid enthaltenden pharmazeutischen Zusammensetzungen Process for the preparation of pharmaceutical compositions containing glimepiride |
| 02/01/2007 | DE102005034406A1 Neue Salze von Rosiglitazon New salts of rosiglitazone |
| 02/01/2007 | DE102005034264A1 4-Chromenonyl-1,4-dihydropyridincarbonitrile und ihre Verwendung 4-Chromenonyl-1,4-dihydropyridincarbonitrile and their use |
| 02/01/2007 | DE102005014904A1 New substituted oxindole derivatives are vasopressin receptor binders useful to treat e.g. diabetes insipidus, enuresis nocturna, incontinence, hypertonia, heart failure, myocardial infarction, coronary spasm and renal disorders |
| 02/01/2007 | DE102004010219B4 HKI10311129, neues Antibiotikum, Verfahren zu dessen Herstellung und Arzneimittel enthaltend HKI10311129 HKI10311129, new antibiotic, to processes for its preparation and medicines containing HKI10311129 |
| 02/01/2007 | DE10141443B4 Verwendung von molekularbiologisch hergestellten, nicht-viralen Wirkstoffen zur Behandlung der Akne Using molecular biological manufactured, non-viral agents for the treatment of acne |
| 02/01/2007 | CA2618218A1 N-(arylamino)-sulfonamide inhibitors of mek |
| 02/01/2007 | CA2618096A1 Carbohydrate compositions from basidiomycete fungi as biocidal agents active against pathogens |
| 02/01/2007 | CA2617353A1 Graded expression of snail as marker of cancer development and dna damage-based diseases |
| 02/01/2007 | CA2617219A1 Compositions comprising fucoidan or a fucoidan hydrolysate and an immuno-stimulating material |
| 02/01/2007 | CA2617183A1 Use of nefopam for the treatment of affective disorders |
| 02/01/2007 | CA2617082A1 Method for genetic immunization by electrotransfer against a toxin and antiserum obtainable by said method |
| 02/01/2007 | CA2617057A1 Method of treating a condition associated with phosphorylation of task-1 |
| 02/01/2007 | CA2617051A1 Ph-controlled pulsatile delivery system, methods for preparation and use thereof |
| 02/01/2007 | CA2617042A1 Spiro-cyclic compound |
| 02/01/2007 | CA2617040A1 Non-invasive drug delivery system targeting posterior eye tissue using solid composition |
| 02/01/2007 | CA2617031A1 Prophylactic/ameliorating agent for menopausal disorder and functional beverage/food |
| 02/01/2007 | CA2617002A1 Method of obtaining a natural hydroxytyrosol-rich concentrate from olive tree residues and subproducts using clean technologies |
| 02/01/2007 | CA2616877A1 Systems and methods for manufacturing liposomes |
| 02/01/2007 | CA2616790A1 Aqueous solution preparation containing camptothecin compounds |
| 02/01/2007 | CA2616768A1 8-methoxy-9h-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents |
| 02/01/2007 | CA2616607A1 Therapeutic protocols using hyaluronan |
| 02/01/2007 | CA2616592A1 Zalcitabine (ddc) boosted lamivudine (3tc) compositions for antiretroviral therapy |
| 02/01/2007 | CA2616576A1 Substituted triazole derivatives and their use as neurokinin 3 receptor antagonists |
| 02/01/2007 | CA2616547A1 Quinoline derivatives as neurokinin receptor antagonists |
| 02/01/2007 | CA2616534A1 Antitumor agent comprising 6'-amidino-2'-naphthyl4- guanidinobenzoate or salt thereof |
| 02/01/2007 | CA2616517A1 Abl kinase inhibition |
| 02/01/2007 | CA2616513A1 Benzylpiperazine derivates useful for the treatment of gastrointestinal disorders |
| 02/01/2007 | CA2616508A1 Pharmaceutical formulation of nitrooxyderivatives of nsaids |
| 02/01/2007 | CA2616377A1 Nitrocatechol derivatives as comt inhibitors |
| 02/01/2007 | CA2616373A1 Octahydroisoquinoline compounds as opioid receptor modulators |
| 02/01/2007 | CA2616314A1 Antiviral phosphonate conjugates for inhibition of hiv |
| 02/01/2007 | CA2616230A1 Method for treating sickle cell disease and sickle cell disease sequelae |
| 02/01/2007 | CA2616224A1 10-substituted tetracyclines and methods of use thereof |
| 02/01/2007 | CA2616222A1 Method for producing tiotropium salts comprising an esterification reaction of methylscopinium and a dithienyl derivative |
| 02/01/2007 | CA2616166A1 Heparin compositions and selectin inhibition |
| 02/01/2007 | CA2616150A1 Inhibition of the renin-angiotensin system for the treatment of renal, vascular and cartilage pathology |